Zacks Research Weighs in on Globus Medical, Inc.’s Q1 2025 Earnings (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research raised their Q1 2025 earnings estimates for Globus Medical in a research note issued to investors on Friday, September 13th. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings per share of $0.76 for the quarter, up from their prior forecast of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.81 EPS and FY2026 earnings at $3.77 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, August 6th. The medical device company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.07. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The company had revenue of $629.69 million for the quarter, compared to analyst estimates of $615.33 million. During the same period in the previous year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 115.9% compared to the same quarter last year.

Several other equities research analysts have also issued reports on GMED. Barclays lifted their price objective on Globus Medical from $85.00 to $93.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a report on Wednesday, August 7th. Truist Financial upped their price objective on shares of Globus Medical from $78.00 to $79.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Royal Bank of Canada lifted their target price on shares of Globus Medical from $76.00 to $78.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, BTIG Research increased their price target on shares of Globus Medical from $75.00 to $77.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $77.20.

Globus Medical Trading Down 0.9 %

GMED stock opened at $69.33 on Monday. The firm has a 50 day moving average of $70.89 and a 200-day moving average of $63.27. The firm has a market capitalization of $9.39 billion, a P/E ratio of 108.33, a price-to-earnings-growth ratio of 1.91 and a beta of 1.17. Globus Medical has a 12 month low of $43.38 and a 12 month high of $74.21.

Insider Activity

In related news, Director Leslie V. Norwalk sold 1,000 shares of Globus Medical stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $70.00, for a total value of $70,000.00. Following the transaction, the director now owns 16,419 shares in the company, valued at approximately $1,149,330. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Globus Medical news, Director Ann D. Rhoads sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $70.36, for a total value of $1,055,400.00. Following the completion of the sale, the director now owns 42,884 shares in the company, valued at $3,017,318.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leslie V. Norwalk sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $70.00, for a total transaction of $70,000.00. Following the completion of the transaction, the director now owns 16,419 shares in the company, valued at approximately $1,149,330. The disclosure for this sale can be found here. 18.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Globus Medical by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 11,277,722 shares of the medical device company’s stock valued at $600,990,000 after acquiring an additional 32,220 shares during the last quarter. Bank of New York Mellon Corp raised its position in Globus Medical by 3.8% during the 1st quarter. Bank of New York Mellon Corp now owns 3,016,702 shares of the medical device company’s stock valued at $161,816,000 after purchasing an additional 110,912 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Globus Medical by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 2,912,454 shares of the medical device company’s stock worth $155,205,000 after buying an additional 252,510 shares during the period. Burgundy Asset Management Ltd. lifted its holdings in Globus Medical by 1.4% in the 2nd quarter. Burgundy Asset Management Ltd. now owns 2,514,891 shares of the medical device company’s stock worth $172,245,000 after buying an additional 35,054 shares during the period. Finally, Champlain Investment Partners LLC grew its position in shares of Globus Medical by 25.2% in the 1st quarter. Champlain Investment Partners LLC now owns 2,504,383 shares of the medical device company’s stock worth $134,335,000 after buying an additional 503,745 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.